MAVENIR
26.2.2024 07:31:31 CET | Business Wire | Press release
Mavenir and QCT collaborate with Intel to introduce the QuantaEdge EGX77B-1U short form factor server to support Open RAN deployments.
The QuantaEdge EGX77B-1U is a short depth (300mm), low power consumption, highly expandable Multi-Access Edge Computing server featuring the 4th Gen Intel Xeon Scalable processor with Intel vRAN Boost and expandable memory for centralized and distributed Radio Access Networks that are ORAN, TIP, and NEBS GR63 Level 3 and GR3108 Class 2 compliant for 4G and 5G services. Detailed specifications of the EGX77B-1U can be found at both the Mavenir and QCT booths at Mobile World Congress.
Mavenir has been working with Intel diligently to harness and realise the benefits of Intel 4th Gen Xeon processors with Intel vRAN boost. The close collaboration has yielded extensive optimisations among the DU software, Intel’s processor, and the latest advancements in Intel’s FlexRAN reference software across 4G and 5G. These new capabilities and features will now be available on DU platforms, including QuantaEdge EGX77B-1U.
Mike Yang, President of QCT said, “QCT is pleased to collaborate with leading partners in the wireless ecosystem, like Mavenir and Intel, to enable innovations taking advantage of 5G Open RAN. By providing standards-compliant, cost-effective, and robust open platforms, QCT is committed to accelerating a diversity of innovative applications not only at the data centre but also at the edge.”
“Mavenir and QCT are at the forefront of industry innovation, offering high-performance Open RAN software and DU platforms powered by Intel’s latest vRAN processor with Intel vRAN Boost – the world’s first vRAN processor with fully integrated acceleration,” said Cristina Rodriguez, Vice President and General Manager, Wireless Access Networking Division at Intel. “Our collaboration reflects a shared commitment to providing flexible solutions designed to meet the widely varying form factor, power consumption, and environmental requirements of global markets.”
Pardeep Kohli, Mavenir CEO said, “Mavenir is excited for this strategic collaboration with QCT and Intel. This new optimised high capacity 1U chip-down edge server broadens our portfolio of options and expands our Open RAN solution blueprint while leveraging the complementary strengths of each of our respective companies.”
The companies will continue to collaborate and work to satisfy customer demands for a diversity of leading-edge performance and cost optimised options when it comes to the design, supply and deployment of open 5G network solutions.
Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.
About QCT:
Quanta Cloud Technology (QCT) is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms, and enterprises running public, hybrid, and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches, and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates, and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. https://www.qct.io/
Meet QCT at Mobile World Congress 2024 at Booth #5E21 in Hall 5.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com.
Meet Mavenir at Mobile World Congress 2024 (Barcelona, Feb 26 – 29 2024)
To explore our latest innovations, MWC show announcements and learn more about how Mavenir is delivering the Future of Networks – Today, visit our team in Hall 2 (Stand 2H60).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240225326148/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom